February 2021

In the next issue of Pharma Technology Focus, we investigate the impact that Amazon Pharmacy’s entry into the online pharmacy space will have on the market, ask if honest brokers could help to bridge the divide between the pharma industry and communities of colour, and find out if the industry response to Covid-19 could provide pharma with a much-needed image makeover.

Plus, we speak to the UK Vaccines Manufacturing and Innovation Centre about the logistics of delivering Covid-19 vaccines to the UK population, examine a new initiative from the World Health Organization that aims to tackle drug resistance and revitalise the antibiotic pipeline, and profile the first weight loss drug to be recommended for use on the NHS in England in almost a decade.

Also, we take a look at a real-time genomic surveillance system for Covid-19 in the UK and explore the potential of ChariotMS, the first multiple sclerosis clinical trial to focus only on people who can’t walk.

EDITORIAL

Editor | Eloise McLennan

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Natalie Healey, Abi Millar, Chloe Kent, Chris Lo, Lise Stevens, Frits Stulp, Anthony Finbow 
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Filipe Costa, Martina Labaiova
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact: Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Is Joe Biden good news for US pharma?Go to article: In this issueGo to article: ContentsGo to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: CommentGo to article: Pipeline agents in the RA marketGo to article: US seeing alarming increases in Covid-19 casesGo to article: IDMP: Where are we now and what lies ahead?Go to article: The rising role of the microbiomeGo to article: What the pandemic highlights about IDMP’s potentialGo to article: In DepthGo to article: Solving the puzzle of Hepatitis CGo to article: Why is President-elect Joe Biden a good pick for the pharma industry?Go to article: Is self-medication the future of pharma?Go to article: Restricted growth: Challenging attitudes to achondroplasiaGo to article: How do you fast-track a vaccine? UCL scientists weigh in Go to article: Fraudulent pharmaceuticals: the legacy of anti-counterfeit packagingGo to article: Are healthcare’s sustainability goals bold enough?Go to article: New Zealand: a promising destination for trials in a post-Covid-19 world?Go to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue